1. BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte
(Home Page/Home Page)

... NIH scientists, Dr. Kovach / Lixte Biotech (OTC: LIXT.OB) have a new publication (Cell Cycle 8:20, 1-4; October 15, 2009) which is entitled, “Enhancement of cancer chemotherapy by simultaneously altering ...

2. Lixte Biotech (OTC: LIXT.OB): A Combination Cancer Killer in Development
(Home Page/Home Page)

Lixte Biotech (OTC: LIXT.OB) (click on the preceding link for my coverage of Lixte at BioMedReports.com) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease ...

3. Small-Cap Stocks Battling Brain Cancer
(Home Page/Home Page)

... is concluded; and (9) recruitment by Oncoscience AG in a Phase 3 trial for adult GBM grade IV will be completed in 2009.   Lixte Biotech (OTC:LIXT) was originally founded as a diagnostics company in ...

4. Small-Cap Stocks Battling Brain Cancer
(MyBlog/MyBlog)

... pontine glioma patients is concluded; and (9) recruitment by Oncoscience AG in a Phase 3 trial for adult GBM grade IV will be completed in 2009.   Lixte Biotech (LIXT.ob) was originally founded ...

5. Lixte Biotech (OTC:LIXT): Preclinical Data Shows Enhancement of Anti-Cancer Treatments
(Home Page/Home Page)

The stock research section of BioMedReports.com has been updated with my 12-page PDF stock profile report for Lixte Biotech (LIXT.ob) (OTC:LIXT) to reflect corporate and preclinical research developments ...

6. Lixte Biotech: Promising Anti-Cancer Compounds in Early Development
(Home Page/Home Page)

Lixte Biotech (LIXT.OB) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery ...

7. Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation
(Home Page/Home Page)

... (NASDAQ:ALTH), Cell Therapeutics (NASDAQ:CTIC), GTx Inc. (NASDAQ:GTXI), Lixte Biotech (OTC:LIXT), Spectrum Pharma (NASDAQ:SPPI), SuperGen (NASDAQ:SUPG), and YM BioSciences (AMEX:YMI). Company Ticker ...

8. Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation
(MyBlog/MyBlog)

... Cell Therapeutics (NASDAQ:CTIC), GTx Inc. (NASDAQ:GTXI), Lixte Biotech (OTC:LIXT), Spectrum Pharma (NASDAQ:SPPI), SuperGen (NASDAQ:SUPG), and YM BioSciences (AMEX:YMI). Company                             ...

9. Lixte Biotech (OTC:LIXT): A Cancer Drug Discovery Spec Buy
(Home Page/Home Page)

Lixte Biotech (OTC:LIXT) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery ...

10. Lixte Biotech (OTC:LIXT): A Cancer Drug Discovery Spec Buy
(MyBlog/MyBlog)

Lixte Biotech (OTC:LIXT) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery ...

11. Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
(News/Latest News)

EAST SETAUKET, N.Y.-- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National ...

12. Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await
(Home Page/Home Page)

Since I first wrote about Lixte Biotech (OTC:LIXT) at BioMedReports.com in early April, the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q ...

13. Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await
(MyBlog/MyBlog)

Since I first wrote about Lixte Biotech (OTC:LIXT) at BioMedReports.com in early April, the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q ...

14. Lixte Biotech: Shifting Focus to Cancer Drug Discovery
(Home Page/Home Page)

Lixte Biotechnology (LIXT.OB) was founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to become a cancer drug discovery ...

15. Lixte Biotech: Shifting Focus to Cancer Drug Discovery
(MyBlog/MyBlog)

Lixte Biotechnology (LIXT.OB) was founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to become a cancer drug discovery ...